Imagion Biosystems Limited advises that the 200,000 Performance Rights issued to Directors of the Company under the Company Long-term Incentive Plan on 14 June 2018, and approved by shareholders at the Company’s Annual General Meeting held on 31 May 2018, have passed the continuous employment vesting condition and have now vested. Accordingly, the Company has today issued 200,000 Fully Paid Ordinary Shares to the Directors as approved by shareholders at the Annual General Meeting held on 31 May 2018.
Appendix 2A — Vesting of Performance Rights
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.